ClinicalTrials.gg
CompletedNCT03721172ADVANCEUpdated May 29, 2024Results posted

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

A Phase 3 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 64 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
595
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
Largest of 44
595 · median 103
Started
2019
with 5 others
Phase 3
18 of 44
none open now
Registered
26th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one has the largest enrollment, is one of 6 that started in 2019, is one of 18 in phase 3, and was the 26th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.

Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

Read the detailed description

The study will consist of four phases:

  • Screening Phase - up to 35 days
  • Double-blind Placebo-controlled Phase - Weeks 0 to 16

    • Subjects will be randomly assigned to either apremilast 30 mg tablets orally BID or placebo tablets (identical in appearance to apremilast 30 mg tablets) orally BID.
  • Apremilast Extension Phase - Weeks 16 to 32

    • All subjects will be switched to (or continue with) apremilast 30 mg BID. All subjects will maintain this dosing through Week 32.
  • Observational Follow-up Phase - 4 weeks - Four-week Post-Treatment Observational Follow-up Phase for all subjects who complete the study or discontinue the study early.
03

Conditions studied

  • Psoriasis

Keywords

  • Phase 3
  • Double-Blind
  • Efficacy
  • Safety
  • Apremilast
  • Otezla
  • CC-10004
  • Plaque Psoriasis
  • Mild
  • Moderate
  • Scalp
  • Nail
  • Itch
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject must be male or female, ≥18 years of age at the time of signing the form (ICF).
  2. Subject must have a diagnosis of chronic plaque psoriasis for at least 6 months prior to signing the ICF.
  3. Subject must have a diagnosis of mild to moderate plaque psoriasis at both Screening and Baseline.
  4. Subject must be inadequately controlled with or intolerant of at least one topical therapy at both Screening and Baseline.
  5. Subject must be in good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.
  6. Subject must meet laboratory criteria.
  7. Subject has not had prior exposure to biologics for the treatment of psoriatic arthritis or psoriasis, or any other condition that could impact the assessment of psoriasis.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Subjects has any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
  1. Subject has surface antigen positive at Screening. 3. Subject has active tuberculosis (TB) or a history of incompletely treated TB.
  1. Subject has history of positive (HIV), or has congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  1. Subject has hepatitis B surface antigen or anti- antibody positive at Screening.
  1. Subject has prior history of suicide attempt at any time in the subject's life time or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the . 7. Subject has current or planned concurrent use of therapies that may have a possible effect on psoriasis during the course of the treatment phase of the trial.
  1. Use of any drug beginning 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
  1. Subject had prior treatment with apremilast.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
595 participants (actual)

Study arms

  • Experimental
    Placebo-controlled Phase:

    Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).

    Other: Placebo

  • Experimental
    Placebo-controlled Phase: Apremilast 30 mg

    Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).

    Drug: Apremilast

  • Experimental
    Extension Phase: Apremilast 30 mg

    Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).

    Drug: Apremilast

Interventions

  • Apremilast, oral, twice daily

  • OtherPlacebo

    Placebo, oral, twice daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase

    The sPGA is a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 =severe. Scores incorporate an assessment by the Investigator of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with at least a 2-point reduction from baseline at Week 16.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

Secondary outcomes

  1. Percentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 16

    The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  2. Change From Baseline in Percentage of Affected BSA at Week 16

    The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area). A negative change from baseline indicates a reduction of affected BSA.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  3. Change From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. A negative change from baseline indicates an improvement of disease symptoms.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  4. Percentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 16

    The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  5. Percentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 4

    The whole body itch NRS is a self-reported measure where participants were asked to assess whole body itch and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A reduction in score from baseline represents an improvement in symptoms.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  6. Percentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 16

    The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an Investigator's assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation of the overall scalp. An ScPGA response is defined as and ScPGA score clear (0) or almost clear (1) with at least a 2-point reduction from baseline among participants with a baseline ScPGA score ≥ 2.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  7. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0 to 30, with 30 corresponding to the worst health-related quality of life, and 0 corresponding to the best score. A negative change from baseline indicates an improvement in health-related quality of life scores.

    Time frame: Baseline and Week 16 of the placebo-controlled phase

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A TEAE is any AE that occurs following administration of study treatment. Frequency of TEAEs was assessed as well as severity and treatment relatedness. A TEAE was considered severe based on the Investigator's assessment. A TEAE could be severe if it was serious or non-serious, had symptoms causing discomfort or pain, requiring medical or surgical attention or intervention, interfered with activities of daily life and if drug therapy was required.

    Time frame: Placebo: Day 1 to Week 16; Apremilast Day 1 to a maximum of Week 32 (plus 4 week safety follow-up)

07

Results

Posted May 17, 2021

Participant flow

Participants were enrolled at 61 research centers in the United States and Canada from March 2019 to July 2020.

Placebo-controlled Phase
Participant flow — Placebo-controlled Phase
MilestonePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgExtension Phase: Apremilast 30 mg
Started2982970
Received at least 1 dose of treatment2972970
Completed2462580
Not completed52390
Withdrew: Adverse event770
Withdrew: Lack of efficacy400
Withdrew: Non-compliance with study drug010
Withdrew: Lost to follow-up15130
Withdrew: Withdrawal by subject23180
Withdrew: Other300
Apremilast Extension Phase
Participant flow — Apremilast Extension Phase
MilestonePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgExtension Phase: Apremilast 30 mg
Started00503
Received at least 1 dose00503
Completed00437
Not completed0066
Withdrew: Adverse event0010
Withdrew: Lack of efficacy002
Withdrew: Non-compliance with study drug001
Withdrew: Lost to follow-up0020
Withdrew: Protocol violation001
Withdrew: Physician decision001
Withdrew: Withdrawal by subject0021
Withdrew: Other003
Withdrew: Other (related to covid-19)007

Outcome measures

PrimaryPercentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase

The sPGA is a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 =severe. Scores incorporate an assessment by the Investigator of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with at least a 2-point reduction from baseline at Week 16.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase4.1 (1.8 to 6.4)21.6 (16.7 to 26.4)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 17.5 · 95% CI 12.2 to 22.82-sided 95% CIs based on the stratified Newcombe method. Stratification were based on baseline sPGA (2 \[mild\] vs 3 \[moderate\]).
SecondaryPercentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 16

The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 16
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a ≥ 75 Percent (%) Improvement From Baseline in Affected Body Surface Area (BSA) at Week 167.4 (4.2 to 10.6)33.0 (27.4 to 38.6)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 25.6 · 95% CI 19.1 to 32.12-sided 95% CIs based on the stratified Newcombe method. Stratification were based on baseline sPGA (2 \[mild\] vs 3 \[moderate\]).
SecondaryChange From Baseline in Percentage of Affected BSA at Week 16

The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area). A negative change from baseline indicates a reduction of affected BSA.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Least squares mean · Percentage change of affected BSA
Change From Baseline in Percentage of Affected BSA at Week 16
Percentage change of affected BSAPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Percentage of Affected BSA at Week 16-0.07 ± 0.24-3.45 ± 0.24
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Mixed-effect model for repeated measures · p = <0.0001 · Least squares mean difference: -3.38 · 95% CI -4.04 to -2.73
SecondaryChange From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. A negative change from baseline indicates an improvement of disease symptoms.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16
Scores on a scalePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 16-0.54 ± 0.20-3.47 ± 0.20
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Mixed-effect model for repeated measures · p = <0.0001 · Least squares mean difference: -2.93 · 95% CI -3.47 to -2.39
SecondaryPercentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 16

The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total body surface area).

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 16
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants Who Achieved BSA ≤ 3% for Participants With Baseline Affected BSA > 3% at Week 1622.9 (17.4 to 28.4)61.0 (54.6 to 67.3)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 38.0 · 95% CI 29.7 to 46.32-sided 95% CIs based on the stratified Newcombe method. Stratification were based on baseline sPGA (2 \[mild\] vs 3 \[moderate\]).
SecondaryPercentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 4

The whole body itch NRS is a self-reported measure where participants were asked to assess whole body itch and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A reduction in score from baseline represents an improvement in symptoms.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 4
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With ≥ 4-point Reduction From Baseline in Whole Body Itch Numeric Rating Scale (NRS) Score at Week 16 Who Had Baseline Whole Body Itch NRS ≥ 418.6 (13.4 to 23.7)43.2 (36.9 to 49.5)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 24.7 · 95% CI 16.5 to 32.82-sided 95% CIs based on the stratified Newcombe method. Stratification were based on baseline sPGA (2 \[mild\] vs 3 \[moderate\]).
SecondaryPercentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 16

The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an Investigator's assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation of the overall scalp. An ScPGA response is defined as and ScPGA score clear (0) or almost clear (1) with at least a 2-point reduction from baseline among participants with a baseline ScPGA score ≥ 2.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Number · Percentage of participants
Percentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 16
Percentage of participantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Percentage of Participants With a Scalp Physician Global Assessment (ScPGA) Response at Week 16 Among Participants With Baseline scPGA Score ≥ 2 at Week 1616.6 (11.1 to 22.2)44.0 (37.1 to 51.0)
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: 27.4 · 95% CI 18.6 to 36.32-sided 95% CIs based on the stratified Newcombe method. Stratification were based on baseline sPGA (2 \[mild\] vs 3 \[moderate\]).
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0 to 30, with 30 corresponding to the worst health-related quality of life, and 0 corresponding to the best score. A negative change from baseline indicates an improvement in health-related quality of life scores.

Time frame:
Baseline and Week 16 of the placebo-controlled phase
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
Scores on a scalePlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mg
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16-2.4 ± 0.3-5.2 ± 0.3
Statistical analysis
  • Placebo-controlled Phase: Placebo vs Placebo-controlled Phase: Apremilast 30 mg · Mixed-effect model for repeated measures · p = <0.0001 · Least squares mean difference: -2.9 · 95% CI -3.7 to -2.1
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A TEAE is any AE that occurs following administration of study treatment. Frequency of TEAEs was assessed as well as severity and treatment relatedness. A TEAE was considered severe based on the Investigator's assessment. A TEAE could be severe if it was serious or non-serious, had symptoms causing discomfort or pain, requiring medical or surgical attention or intervention, interfered with activities of daily life and if drug therapy was required.

Time frame:
Placebo: Day 1 to Week 16; Apremilast Day 1 to a maximum of Week 32 (plus 4 week safety follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremalist: Placebo-controlled Phase and Extension Phase
Any TEAE139195351
Severe TEAE2824
Treatment-related TEAE36110186

Adverse events

Collected over Placebo: Day 1 to Week 16; Apremilast Day 1 to a maximum of Week 32 (plus 4 week safety follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Phase: Placebo0/296 (0%)4/296 (1.4%)51/296 (17.2%)
Placebo-controlled Phase: Apremilast 30 mg0/298 (0%)1/298 (0.3%)118/298 (39.6%)
Apremalist: Placebo-controlled Phase and Extension Phase0/544 (0%)12/544 (2.2%)208/544 (38.2%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremalist: Placebo-controlled Phase and Extension Phase
PneumoniaInfections and infestations1/2960/2983/544
Cardiac failure congestiveCardiac disorders1/2960/2980/544
Pneumonia pneumococcalInfections and infestations1/2960/2980/544
Migraine without auraNervous system disorders1/2960/2980/544
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/2960/2980/544
Angina pectorisCardiac disorders0/2961/2981/544
Myocardial ischaemiaCardiac disorders0/2961/2981/544
Cardiac failureCardiac disorders0/2960/2981/544
Myocardial infarctionCardiac disorders0/2960/2981/544
Abdominal painGastrointestinal disorders0/2960/2981/544
Most frequent other events
Most frequent other events
EventPlacebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgApremalist: Placebo-controlled Phase and Extension Phase
DiarrhoeaGastrointestinal disorders15/29649/29878/544
HeadacheNervous system disorders15/29639/29870/544
NauseaGastrointestinal disorders13/29638/29869/544
Upper respiratory tract infectionInfections and infestations15/29617/29846/544
NasopharyngitisInfections and infestations8/29622/29837/544

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Mean48.3 ± 14.4549.2 ± 14.6548.7 ± 14.55
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Female147123270
Male151174325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
Hispanic or Latino333164
Not Hispanic or Latino260264524
Unknown or Not Reported527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
American Indian or Alaska Native178
Asian181533
Native Hawaiian or Other Pacific Islander123
Black or African American171431
White257254511
More than one race000
Unknown or Not Reported459
Static Physician Global Assessment (sPGA) Score
Static Physician Global Assessment (sPGA) Score(Participants)Placebo-controlled Phase: PlaceboPlacebo-controlled Phase: Apremilast 30 mgTotal
2 (mild)9191182
3 (moderate)207206413
08

Study locations

64 sites
  • Total Skin & Beauty Dermatology Center
    Birmingham, Alabama 35205, United States
  • Johnson Dermatology Clinic
    Fort Smith, Arkansas 72916, United States
  • Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology
    Rogers, Arkansas 72758, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • TCR Medical Corporation
    San Diego, California 92123, United States
  • University of California San Francisco Psoriasis and Skin Treatment Center
    San Francisco, California 94118, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • University of Colorado Hospital - Dermatology Clinic
    Aurora, Colorado 80045, United States
  • Total Vein and Skin, LLC
    Boynton Beach, Florida 33437, United States
  • Florida Academic Centers Research and Education
    Coral Gables, Florida 33134, United States
  • International Dermatology Research
    Miami, Florida 33144, United States
  • Center for Clinical and Cosmetic Research
    Miami, Florida 33180, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • University of South Florida - Carol and Frank Morsani Center for Advanced Health Care
    Tampa, Florida 33612, United States
  • Atlanta Dermatology, Vein and Research Center, PC
    Alpharetta, Georgia 30022, United States
  • Medical Dermatology Specialists, Inc. - Advanced Medical Research
    Atlanta, Georgia 30328, United States
  • MedaPhase INC
    Newnan, Georgia 30263, United States
  • Gwinnett Clinical Research Center, Inc.
    Snellville, Georgia 30078, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Clinical Trials Management LLC
    Metairie, Louisiana 70006, United States
  • Derm Associates
    Rockville, Maryland 20850, United States
  • Lawrence Green, MD, LLC
    Rockville, Maryland 20850, United States
  • ActivMed Practices & Research Inc
    Beverly, Massachusetts 01915, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2517, United States
  • Henry Ford Medical Center - New Center One
    Detroit, Michigan 48202, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • JDR Dermatology Research, LLC
    Las Vegas, Nevada 89148, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Albert Einstein College of Medicine - Montefiore Medical Center
    Bronx, New York 10467, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10003, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Wright State Physicians
    Fairborn, Ohio 45324, United States
  • Temple University - Lewis Katz School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • University of Utah MidValley Dermatology
    Murray, Utah 84107, United States
  • Virginia Clinical Research Inc
    Norfolk, Virginia 23502, United States
  • Dermatology Center for Skin Health
    Morgantown, West Virginia 26505, United States
  • Institute for Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • Chih-Ho Hong Medical, Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Winnipeg Clinic Dermatology Research
    Winnipeg, Manitoba R3CON2, Canada
  • SkinWise Dermatology
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Brunswick Dermatology Centre
    Fredericton, New Brunswick E3B 1G9, Canada
  • Karma Clinical Trials
    Saint John's, Newfoundland and Labrador A1A 4Y3, Canada
  • SimcoDerm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Guelph Dermatology Research
    Guelph, Ontario N1L 0B7, Canada
  • DermEffects
    London, Ontario N6H 5L5, Canada
  • Lynderm Research
    Markham, Ontario L3P 1X2, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Skin Center for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Toronto Research Centre
    Toronto, Ontario M3H 5Y8, Canada
  • Sameh Hanna Medicine Professional Corporation DBA Dermatology on Bloor
    Toronto, Ontario M4W 2N2, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Windsor Clinical Research Inc.
    Windsor, Ontario N8W 5L7, Canada
  • Dr Isabelle Delorme inc
    Drummondville, Quebec J2B 5L4, Canada
  • Dre Angelique Gagne-Henley M.D. Inc.
    Saint-Jerome, Quebec J7Z 7E2, Canada
  • Skinsense Medical Research
    Saskatoon, Saskatchewan S7K 0H6, Canada
09

References and documents

Publications

  • Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022 Jan;86(1):77-85. doi: 10.1016/j.jaad.2021.07.040. Epub 2021 Jul 31. PubMed 34343599 ↗
  • Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, Shi R, Flower A, Picard H, Stein Gold L. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behcet's Syndrome. Am J Clin Dermatol. 2023 Sep;24(5):809-820. doi: 10.1007/s40257-023-00783-7. Epub 2023 Jun 14. PubMed 37316690 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Mar 2020, 11 months.

Results were first posted in May 2021, 1 year 2 months after primary completion. A results delay was requested in Nov 2020.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2018
First posted
Oct 26, 2018
StartActual
Mar 11, 2019
Primary completionActual
Mar 6, 2020
CompletionActual
Jul 24, 2020
Results delay requested
Nov 4, 2020
Results first posted
May 17, 2021
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03721172
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Mar 11, 2019
Primary completion
Mar 6, 2020
Completion
Jul 24, 2020
Results posted
May 17, 2021
Last update
May 29, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion